Connection

Co-Authors

This is a "connection" page, showing publications co-authored by MIEN-CHIE HUNG and LEI NIE.
Connection Strength

4.694
  1. Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells. Am J Cancer Res. 2023; 13(4):1209-1239.
    View in: PubMed
    Score: 0.890
  2. Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2020 Jan 29; 11(1):673.
    View in: PubMed
    Score: 0.712
  3. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2019 11 08; 10(1):5114.
    View in: PubMed
    Score: 0.701
  4. Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. Am J Transl Res. 2012; 4(2):127-50.
    View in: PubMed
    Score: 0.414
  5. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022 10; 3(10):1211-1227.
    View in: PubMed
    Score: 0.215
  6. Author Correction: PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020 Nov; 22(11):1396.
    View in: PubMed
    Score: 0.188
  7. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020 10; 22(10):1264-1275.
    View in: PubMed
    Score: 0.186
  8. Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERa expression in high-grade serous ovarian carcinoma. Am J Cancer Res. 2020; 10(4):1194-1206.
    View in: PubMed
    Score: 0.180
  9. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res. 2020; 10(2):648-661.
    View in: PubMed
    Score: 0.178
  10. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019 07 15; 129(8):3324-3338.
    View in: PubMed
    Score: 0.171
  11. Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. Am J Cancer Res. 2019; 9(3):608-618.
    View in: PubMed
    Score: 0.167
  12. Targeting PKCd as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. Cancer Cell. 2018 12 10; 34(6):954-969.e4.
    View in: PubMed
    Score: 0.165
  13. GSK3? inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. 2016 Aug 30; 7(35):57131-57144.
    View in: PubMed
    Score: 0.141
  14. Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. Am J Cancer Res. 2015; 5(12):3624-34.
    View in: PubMed
    Score: 0.133
  15. Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. Am J Transl Res. 2015; 7(6):1009-20.
    View in: PubMed
    Score: 0.129
  16. Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells. Am J Transl Res. 2014; 6(6):649-63.
    View in: PubMed
    Score: 0.124
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.